10-Q: Arcus Biosciences Reports Q3 Loss Amid R&D Surge, Key Clinical Progress

Arcus Biosciences reported a significant increase in net loss for Q3 2025 despite advancing its late-stage clinical pipeline and securing new collaboration milestones.

Summary

• Net loss for the three months ended September 30, 2025, increased by 47% to $135 million, compared to $92 million for the same period in 2024.
• Total revenues decreased by 46% to $26 million for Q3 2025 from $48 million in Q3 2024, primarily due to lower development service revenues from the Gilead Collaboration and the absence of a prior year license revenue from Taiho.
• Research and development (R&D) expenses rose by 15% to $141 million in Q3 2025, driven by increased enrollment and start-up activities for late-stage programs PRISM-1 and PEAK-1.
• As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $841 million, which is believed to be sufficient to fund planned operations for at least twelve months and through initial pivotal read-outs for domvanalimab, quemliclustat, and casdatifan.
• Taiho Pharmaceutical exercised its option for an exclusive license to casdatifan (HIF-2 program) in Japan and certain other Asian territories in October 2025, with a $15 million option payment due in Q4 2025.
• Enrollment for the Phase 3 PRISM-1 trial of quemliclustat in first-line metastatic pancreatic ductal adenocarcinoma was completed within 12 months of study initiation in October 2025.
• Gilead Sciences, Inc. returned its license to the etrumadenant (adenosine receptor antagonist) program in Q2 2025, resulting in a $143 million cumulative revenue catch-up.
• Recruitment for the eVOLVE-RCC02 Phase 1b/3 study, evaluating casdatifan plus volrustomig in first-line metastatic clear cell renal cell carcinoma, was temporarily paused in October 2025 due to observations of potentially immune-mediated adverse events.

Sentiment

Score: 5

Explanation: The company reported increased net losses and decreased revenues, reflecting higher R&D investments and changes in collaboration agreements. However, positive clinical data for key assets (casdatifan, domvanalimab) and the efficient completion of Phase 3 enrollment for quemliclustat provide a positive counterpoint. The temporary pause in a combination study due to adverse events and Gilead's termination of a license are notable negatives, but the company maintains a strong cash position to fund operations through critical milestones.

Positives

• Taiho Pharmaceutical exercised its option for casdatifan (HIF-2 program) for the Taiho Territory in October 2025, including a $15 million option payment and potential future milestones/royalties.
• New data from the Phase 1/1b ARC-20 study for casdatifan in late-line metastatic kidney cancer showed promising efficacy, with a median progression-free survival (mPFS) of 12.2 months and a confirmed overall response rate (cORR) of 31% in the pooled analysis.
• The 100mg QD cohort of ARC-20 (Phase 3 PEAK-1 dose) showed mPFS not reached and a 12-month landmark PFS of 60%, with a cORR of 35%.
• Casdatifan demonstrated an acceptable and manageable safety profile across all doses in the ARC-20 study.
• First overall survival (mOS) results from the Phase 2 EDGE-Gastric study for domvanalimab plus zimberelimab and chemotherapy showed 26.7 months in the overall patient population, with mOS not reached in patients with PD-L1 expression ≥5%.
• The safety profile of domvanalimab plus zimberelimab and chemotherapy in EDGE-Gastric was generally well tolerated and consistent with anti-PD-1 plus chemotherapy.
• Completed enrollment of the Phase 3 PRISM-1 trial for quemliclustat in first-line metastatic pancreatic ductal adenocarcinoma within 12 months of study initiation.
• Maintained a strong liquidity position with $841 million in cash, cash equivalents, and marketable securities as of September 30, 2025, sufficient to fund operations for at least 12 months and through initial pivotal read-outs.
• R&D expenses are expected to decline meaningfully after 2025 as the domvanalimab Phase 3 development program costs decrease.

Negatives

• Net loss significantly increased by 47% to $135 million for the three months ended September 30, 2025, compared to $92 million for the same period in 2024.
• Total revenues decreased by 46% to $26 million for the three months ended September 30, 2025, primarily due to lower development service revenues from the Gilead Collaboration and the absence of a prior year license revenue from Taiho.
• Net cash used in operating activities increased substantially to $362 million for the nine months ended September 30, 2025, compared to $70 million for the same period in the prior year.
• Gilead returned its license to the etrumadenant (adenosine receptor antagonist) program in Q2 2025, indicating a discontinuation of development for this asset by Gilead.
• Gilead's time-limited exclusive option rights to the HIF-2 program (casdatifan) expired in Q1 2025, meaning Gilead will not pursue this program.
• Recruitment for the eVOLVE-RCC02 Phase 1b/3 study (casdatifan plus volrustomig) was temporarily paused in October 2025 due to observations of potentially immune-mediated adverse events, requiring further monitoring and discussions with health authorities.
• The BVF Program for inflammatory diseases was discontinued in Q1 2025 due to new preclinical information decreasing the likelihood of achieving regulatory and commercial success.
• Long-term debt increased to $98 million as of September 30, 2025, from $48 million at December 31, 2024, following an additional $50 million draw from Hercules Capital.

Risks

• The company has a history of operating losses, has never generated revenue from product sales, and anticipates incurring significant losses for the foreseeable future.
• Additional funding may be required, and if not obtained, operations may be restricted or product development programs delayed, reduced, or eliminated.
• Inability to obtain regulatory approval for investigational products, or significant delays in doing so, would materially harm the business.
• Preliminary, topline, and interim data from clinical studies are subject to audit and verification, which could result in material changes in the final data.
• Enrollment and retention of subjects in clinical trials are expensive, time-consuming, and can be made difficult by competing treatments, geopolitical instability, and public health epidemics.
• Serious adverse events, undesirable side effects, or other unexpected properties of investigational products may be identified, leading to discontinuation or limitations.
• Failure in the strategy of developing intra-portfolio combinations to achieve superior outcomes relative to single agents or other combination therapies would impair strategic objectives.
• Certain investigational products may require companion diagnostics; failure to successfully develop, validate, and obtain regulatory clearance or approval for such tests could harm product development.
• Dependence on the collaboration with Gilead Sciences, Inc. for research, development, manufacture, and commercialization poses risks of conflicts or adverse effects if the collaboration is unsuccessful.
• Reliance on third parties to conduct clinical trials and perform research and preclinical studies; failure to satisfactorily carry out duties or meet deadlines could delay development programs.
• Even with marketing approval, commercialization of investigational products may not be successful due to various factors, including market acceptance and sales capabilities.
• Commercial success is dependent on obtaining coverage and reimbursement approval from government or other third-party payors, which may be delayed or insufficient to cover costs.
• Obtaining and maintaining regulatory approval in one jurisdiction does not guarantee approval in any other jurisdiction.
• Investigational products intended for approval as biologic products may face competition sooner than anticipated due to biosimilar pathways.
• Breach of obligations under in-license agreements could result in damages or loss of rights to investigational products.
• Inability to obtain and maintain sufficient intellectual property protection, or if the scope is not broad enough, competitors could develop and commercialize similar products.
• Potential involvement in lawsuits alleging intellectual property infringement or to protect/enforce patents, which could be expensive and time-consuming.
• Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents.
• Reliance on trade secrets and proprietary know-how, which can be difficult to trace and enforce, and if confidentiality is not protected, competitive position would be harmed.
• Expected expansion of business operations may lead to difficulties in managing growth, potentially disrupting operations.
• Substantial competition in the industry may result in others discovering, developing, or commercializing products more quickly or successfully.
• Internal information technology systems and those of third-party CROs are subject to failure, security breaches, and other disruptions, potentially jeopardizing sensitive information.
• Failure to comply with privacy and data protection laws, regulations, or other obligations could lead to government enforcement actions, private litigation, and/or adverse publicity.
• Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact the business unpredictably.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization.
• Unfavorable global economic, political, and trade conditions (e.g., US-China tensions affecting WuXi Biologics, inflation) could adversely affect the business.
• Future growth may depend on the ability to operate in foreign markets, subject to additional regulatory burdens and risks.
• Adverse effects from earthquakes, fires, or other natural disasters, particularly given the concentration of facilities in the San Francisco Bay Area.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited by ownership changes or state tax laws.
• Changes in tax laws and regulations or exposure to additional tax liabilities could adversely affect financial results.
• The stock price of common stock has been and may continue to be volatile or may decline regardless of operating performance.
• Quarterly operating results may fluctuate significantly or fall below expectations, causing stock price to fluctuate or decline.
• Concentration of stock ownership (e.g., Gilead's 29.3%) may limit other stockholders' ability to influence corporate matters.
• Delaware law and provisions in the amended and restated certificate of incorporation and bylaws could make a merger, tender offer, or proxy contest difficult, depressing the trading price of common stock.

Future Outlook

R&D expenses are expected to peak in 2025 and then decline meaningfully over the next few years as programs advance towards regulatory approval. The company anticipates advancing new programs into the clinic, which will require significant growth in development capabilities and infrastructure. G&A expenses are expected to remain stable for the remainder of the year. Current cash, cash equivalents, and marketable securities are believed to be sufficient to fund planned operations for at least twelve months and through initial pivotal read-outs for domvanalimab, quemliclustat, and casdatifan (including PEAK-1).

Management Comments

• We are a clinical-stage biopharmaceutical company focused on creating best-in-class therapies.
• Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies targeting lung and GI cancers.
• Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.
• Our vision is to create, develop and commercialize highly differentiated therapies that have a meaningful impact on patients.
• We expect our R&D expenses to peak in 2025 and then decline meaningfully during the next few years as we advance our programs towards regulatory approval.
• We anticipate that our G&A expenses will be stable for the remainder of this year.
• Based on our existing business plan, our cash, cash equivalents, marketable securities and existing facilities as of September 30, 2025 will be sufficient to fund our planned level of operations for a period of at least twelve months and provide funding through our initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan, which include PEAK-1.

Industry Context

The company operates in the highly competitive immuno-oncology and cancer therapeutics market, characterized by rapidly changing standards of care. Its focus on developing intra-portfolio combinations aligns with a broader industry trend of seeking synergistic effects in combination therapies, though this strategy inherently involves complex development challenges. The temporary pause in a Phase 1b/3 study due to adverse events highlights the inherent safety challenges and regulatory scrutiny common in early-stage clinical development within the biopharmaceutical sector. The dynamic nature of large pharmaceutical collaborations is evident with Gilead's termination of one license and expiration of an option for another program, while Taiho's exercise of an option for casdatifan demonstrates continued partner interest in specific assets. The efficient completion of Phase 3 enrollment for quemliclustat showcases effective clinical execution, a key competitive differentiator in the industry.

Comparison to Industry Standards

• The company's strategy of developing intra-portfolio combinations is a common approach in immuno-oncology, aiming to achieve superior outcomes compared to single agents, similar to strategies pursued by major pharmaceutical companies in the cancer treatment space.
• The reported median progression-free survival (mPFS) of 12.2 months and confirmed overall response rate (cORR) of 31% for casdatifan in late-line metastatic kidney cancer (ARC-20 study) are notable, especially for a patient population that has progressed on multiple prior lines of therapy, and would be evaluated against existing approved therapies and other investigational HIF-2 inhibitors or TKIs in the renal cell carcinoma landscape.
• The median overall survival (mOS) of 26.7 months for domvanalimab plus zimberelimab and chemotherapy in the EDGE-Gastric study for advanced gastric/GEJ/esophageal adenocarcinoma provides a benchmark for combination therapies in this difficult-to-treat cancer, and would be compared to standard-of-care regimens and other anti-PD-1/TIGIT combinations in development by competitors like Merck (Keytruda/vibostolimab) and Roche (Tecentriq/tiragolumab).
• The rapid completion of enrollment for the Phase 3 PRISM-1 trial for quemliclustat in pancreatic cancer within 12 months of study initiation demonstrates efficient clinical trial execution, which is a positive operational indicator compared to typical timelines for large-scale oncology trials.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• From time to time, the company may become involved in legal proceedings arising in the ordinary course of business, which could have an adverse impact due to defense and settlement costs, diversion of management resources, and reputational harm.

Related Party Transactions

• Gilead Sciences, Inc. (related party): Recognized $26 million in revenue for the three months ended September 30, 2025, and $214 million for the nine months ended September 30, 2025, under the Gilead Agreements. Recognized net expense to Gilead of $16 million and $24 million for the three and nine months ended September 30, 2025, respectively. Had a net payable to Gilead of $29 million as of September 30, 2025. Gilead purchased 1.4 million shares of common stock for $15 million in the Q1 2025 underwritten offering and holds approximately 29.3% of outstanding common stock. Gilead returned its license to the etrumadenant program in Q2 2025, and its time-limited exclusive option rights to the HIF-2 program expired in Q1 2025.
• Taiho Pharmaceutical Co., Ltd (collaboration partner): Recognized net reimbursements from Taiho of $7 million and $24 million for the three and nine months ended September 30, 2025, respectively, as a reduction in R&D expense. Had $11 million receivable from collaboration partners as of September 30, 2025, and $42 million in liabilities related to advance cost sharing payments. Taiho exercised its option for casdatifan in October 2025 for a $15 million payment and became obligated to make $19 million in milestone payments for PRISM-1 ($12 million received Q1 2025, $7 million due Q1 2026).

Stakeholder Impact

• Shareholders: Experienced increased net losses and decreased revenues, which could negatively impact share price. However, positive clinical data for key programs and a strong liquidity position may provide some confidence. Potential for future dilution from capital raises remains.
• Employees: Continued investment in R&D and anticipated growth in development capabilities suggest ongoing employment opportunities, though program discontinuations (etrumadenant, BVF Program) could affect specific teams.
• Collaboration Partners: Gilead's termination of the etrumadenant license and expiration of the HIF-2 option indicate a shift in its portfolio focus. Taiho's exercise of the casdatifan option strengthens that partnership. AstraZeneca's pause in the eVOLVE-RCC02 study requires joint monitoring and decision-making.
• Patients: Advancement of multiple Phase 3 programs (domvanalimab, quemliclustat, casdatifan) offers potential new therapies for various cancers. The temporary pause in the eVOLVE-RCC02 study could delay a potential treatment option for clear cell renal cell carcinoma.
• Creditors (Hercules Capital): The company drew an additional $50 million in debt, increasing its leverage, but its reported sufficient liquidity provides near-term comfort regarding repayment capacity.

Next Steps

• Monitor participants in the eVOLVE-RCC02 study to further characterize the safety profile of the casdatifan/volrustomig combination and engage in discussions with health authorities to inform next steps for the study.
• Taiho Pharmaceutical is obligated to make a $15 million option payment for casdatifan in the fourth quarter 2025.
• Taiho Pharmaceutical is obligated to make a $7 million milestone payment for PRISM-1 in the first quarter 2026.
• Gilead has the right to reinstate PACIFIC-8 as part of the parties' joint development activities for the TIGIT Program in the first quarter 2026.
• Advance new programs into the clinic, requiring significant growth in development capabilities and infrastructure.
• Increase late-stage manufacturing activities as clinical-stage programs advance and prepare for regulatory approval.
• Continue to assess the potential impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-07) on financial statements and disclosures.
• Seek additional funding through equity sales, debt financings, or other capital sources, including existing or potential collaborations, if needed to support long-term development strategy.

Key Dates

Recommendation

The company faces significant financial challenges with increasing losses and decreasing revenues, reflecting the high cost of clinical development. The termination of the etrumadenant license by Gilead and the temporary pause in the eVOLVE-RCC02 study due to adverse events are concerning. However, the positive clinical data for casdatifan and domvanalimab, along with the efficient advancement of quemliclustat into Phase 3, demonstrate pipeline progress. The company's strong cash position provides a runway through key pivotal read-outs, mitigating immediate liquidity concerns. Given the mixed financial and clinical signals, a 'Hold' recommendation is appropriate, awaiting further clarity on clinical outcomes and a path to profitability.

Keywords

Arcus Biosciences, Biopharmaceutical, Clinical-stage, Immuno-oncology, Cancer therapies, TIGIT antibody, Domvanalimab, HIF-2 inhibitor, Casdatifan, CD73 program, Quemliclustat, Pancreatic cancer, Kidney cancer, Gastric cancer, NSCLC, Gilead Sciences, Taiho Pharmaceutical, AstraZeneca, Clinical trials, Phase 3, Drug development, Biologics, SEC filing, 10-Q, Financial results, Biotech investment